Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive - Investor's Business Daily

What the report says

Investor’s Business Daily reported that Tempus AI said Monday it plans to acquire Personalis, a cancer diagnostics company, in a deal valued at $1.5 billion. The announcement did not lift investor sentiment: IBD said shares of both Tempus AI and Personalis moved lower after the news.

Personalis develops cancer-testing products, including NeXT Personal, described in the report as a blood test that looks for circulating tumor DNA. Such tests are part of a broader field often called liquid biopsy, which aims to help detect or monitor cancer-related genetic material from a blood sample rather than relying only on tissue-based testing. The article did not provide additional transaction terms in the accessible text.

The deal follows recent takeover speculation. IBD reported that a rumor last week had linked Merck and other possible buyers, including Tempus AI, to interest in Personalis. The accessible article text does not say whether Merck made a formal offer or whether any competing bid remains active.

The proposed acquisition matters because it would combine Tempus AI, a company associated with data-driven medical technology, with a diagnostics business focused on cancer monitoring. For investors, the immediate share declines suggest questions about valuation, integration, financing or competitive dynamics, though IBD’s available text does not specify the market’s exact concerns. The transaction also highlights continuing interest in oncology diagnostics, where companies are seeking tools that can support treatment decisions and disease tracking.